Home Forums Other Specialities Therapeutics HYDROXYCHLOROQUINE AND COVID

This topic contains 1 voice and has 0 replies.
1 voice
0 replies
  • Author
    Posts
  • #2706
    Anonymous
    Inactive

    WHO SOLIDARITY TRIAL FOR COVID

    Why was the use of hydroxychloroquine stopped in the Solidarity Trial?
    On 17 June 2020, WHO announced that the hydroxychloroquine (HCQ) arm of the Solidarity Trial to find an effective COVID-19 treatment was being stopped.

    The trial’s Executive Group and principal investigators made the decision based on evidence from the Solidarity trial, UK’s Recovery trial and a Cochrane review of other evidence on hydroxychloroquine.

    Data from Solidarity (including the French Discovery trial data) and the recently announced results from the UK’s Recovery trial both showed that hydroxychloroquine does not result in the reduction of mortality of hospitalised COVID-19 patients, when compared with standard of care.

    The use of hydroxychloroquine and chloroquine are accepted as generally safe for use in patients with autoimmune diseases or malaria.

    What is WHO’s view of the use of hydroxychloroquine in pre or post-exposure prophylaxis?

    The decision to stop hydroxychloroquine’s use in the Solidarity trial does not apply to the use or evaluation of hydroxychloroquine in pre or post-exposure prophylaxis in patients exposed to COVID-19.

    What is the Solidarity Trial?

    The Solidarity Trial is an international clinical trial to help find an effective treatment for COVID-19, launched by WHO and partners. It is hoped that one or more of the treatments under trial will result in improving clinical outcomes in COVID-19 patients and save lives. Other trials are on-going around the world in addition to the Solidarity Trial.

    The treatment options are: Remdesivir; Lopinavir/Ritonavir; and Lopinavir/Ritonavir with Interferon beta-1a. The treatment options were originally selected based on evidence from laboratory, animal and clinical studies.

You must be logged in to reply to this topic.